source
- FDA advisory panel backs broader use of wellness peptide BPC-157 despite internal concernsThe FDA advisory committee voted Thursday to recommend loosening restrictions on BPC-157, a peptide popular among health and wellness enthusiasts for muscle repair, injury healing, metabolism suppo…
- Lilly's obesity drug shows strong weight loss but fails to demonstrate cardiovascular benefit in heart disease trialEli Lilly released Phase 3 results for its next‑generation obesity therapy retatrutide, showing it produces substantial weight loss in a trial of nearly 2,000 participants with severe obesity and e…